Enzychem Lifesciences Corporation (KOSDAQ:183490)

Market Cap	76.86B -29.6%
Revenue (ttm)	61.86B -18.5%
Net Income	-18.12B
EPS	-234.70
Shares Out	77.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	677,473
Open	1,003.00
Previous Close	1,017.00
Day's Range	986.00 - 1,012.00
52-Week Range	937.00 - 1,766.00
Beta	0.88
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Enzychem Lifesciences

Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 130
• Stock Exchange: KOSDAQ
• Ticker Symbol: 183490

Financial Performance

In 2025, Enzychem Lifesciences's revenue was 67.75 billion, a decrease of -12.44% compared to the previous year's 77.38 billion. Losses were -18.13 billion, -17.98% less than in 2024.